HURA - NASDAQ
TuHURA Biosciences, Inc.
$2.12
+2.4%TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
At a Glance
Live SnapshotTuHURA Biosciences, Inc. Management Team
Mr. Michael Lawman
Co-Founder
Ms. Patricia Lawman
Co-Founder
Mr. Dan Dearborn CPA
Executive Vice President of Finance & Chief Financial Officer
Compensation
$339,101
Dr. Bertrand Le Bourdonnec Ph.D.
Executive Vice President, Head of Drug Discovery, Early Development, & Program Management
Mr. Michael Krsulich
Head of Quality Assurance
Dr. James A. Bianco M.D.
President, Chief Executive Officer & Director
Compensation
$543,734
TuHURA Biosciences, Inc. Insider Positioning
During the last 12 months, there has been no insider trading activity reported for HURA.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
SEC Filings
HURA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2024 N/A | May 17, 2024 | June 20, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | September 11, 2023 | October 09, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | March 31, 2023 | May 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | May 06, 2022 | June 21, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | May 07, 2021 | June 25, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | June 02, 2020 | June 26, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | May 14, 2019 | June 26, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 09, 2018 | March 12, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.